Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis

Pharmacogenomics

Volumn 10, Issue 11, 2009, Pages 1767-1779

  Kim, Sang Heon ^b   Kim, Sang Hoon ^c   Bahn, Joon Woo ^d   Kim, Yoon Keun ^e   Chang, Yoon Seok ^f   Shin, Eun Soon ^g   Kim, Youn Seup ^a   Park, Jae Seuk ^a   Kim, Bo Hyung ^f   Jang, In Jin ^f   Song, Junghan ^f   Kim, Seung Hyun ^h   Park, Hae Sim ^h   Min, Kyung Up ^f   Jee, Young Koo ^a  

^a Dankook University College of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Eulji University   (South Korea)

^d Hallym University College of Medicine   (South Korea)

^e Pohang University of Science and Technology (POSTECH)   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g DNA Link Inc   (South Korea)

^h Ajou University School of Medicine   (South Korea)

Author keywords

Anti TB drug; Drug metabolizing enzyme; Hepatitis; N acetyltransferase 2; Polymorphism

Indexed keywords

ALANINE; ARGININE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; ETHAMBUTOL; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUTAMINE; ISONIAZID; LUCIFERASE; PYRAZINAMIDE; RIFAMPICIN; THREONINE; TUBERCULOSTATIC AGENT;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; KOREA; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; WILD TYPE;

ACETYLATION; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; HAPLOTYPES; HUMANS; ISONIAZID; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70649093029     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.100     Document Type: Article

References (41)

1. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293, 2767-2775 (2005). (Pubitemid 40965089)
2. Blumberg HM, Burman WJ, Chaisson RE et al.: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
3. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 53, 536-548 (1998).
4. Saukkonen JJ, Cohn DL, RM Jasmer et al.: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 174, 935-952 (2006). ■■ American Thoracic Society guidelines state current understandings of definition, pathophysiology, risk factors, prevention and management of drug-induced liver injury.
5. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK: Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51, 132-136 (1996). (Pubitemid 26060649)
6. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 166, 916-919 (2002). ■ Revealed significant association of HLA alleles with anti-TB drug-induced hepatitis.
7. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167, 1472-1477 (2003). (Pubitemid 37363354)
8. Yew WW, Leung CC: Antituberculosis drugs and hepatotoxicity. Respirology 11, 699-707 (2006).
9. Lee WM: Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485 (2003). ■ Review article that summarizes the pathogenic mechanisms of drug-induced hepatotoxicity.
10. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK: Reactive metabolites and their role in drug reactions. Curr. Opin. Allergy Clin. Immunol. 1, 317-325 (2001).
11. Huang YS, Chern HD, WJ Su et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35, 883-889 (2002). ■■ Taiwanese study reported significant association between NAT2 genotypes with slow acetylator phenotype and anti-TB drug-induced hepatitis.
12. Shimizu Y, Dobashi K, Y Mita et al.: DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb.) 86(5), 374-381 (2005). (Pubitemid 44189952)
13. Kita T, Tanigawara Y, S Chikazawa et al.: N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol. Pharm. Bull. 24, 544-549 (2001). (Pubitemid 32499483)
14. Hiratsuka M, Kishikawa Y, Takekuma Y et al.: Genotyping of the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet. 17, 357-362 (2002).
15. Ohno M, Yamaguchi I, Yamamoto I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4, 256-261 (2000). (Pubitemid 30151575)
16. Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb.) 87, 551-556 (2007).
17. Higuchi N, Tahara N, Yanagihara K et al.: NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 13, 6003-6008 (2007). (Pubitemid 350252844)
18. Possuelo LG, Castelan JA, de Brito TC et al.: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 64, 673-681 (2008).
19. Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37, 924-930 (2003). ■ Significant association of CYP2E1 polymorphisms with anti-TB drug-induced hepatitis was reported in Taiwan.
20. Roy B, Chowdhury A, Kundu S et al.: Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Gastroenterol. Hepatol. 16, 1033-1037 (2001). ■■ GSTM1 null mutation was reported to increase risk of anti-TB drug-induced hepatitis in India.
21. Leiro V, Fernandez-Villar A, Valverde D et al.: Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 28, 835-839 (2008). (Pubitemid 351818646)
22. Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 11, 272-276 (1990).
23. Holden AL: The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques (Suppl. 22-24), 26 (2002).
24. Han W, Kang D, Lee JE et al.: A haplotype ana lysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin. Cancer Res. 11, 4775-4778 (2005). (Pubitemid 41557198)
25. Song SH, Jun SH, Park KU et al.: Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21, 1331-1338 (2007).
26. Urban A, Neukirchen S, Jaeger KE: A rapid and efficient method for site-directed mutagenesis using one-step overlap extension PCR. Nucleic Acids Res. 25, 2227-2228 (1997). (Pubitemid 27303460)
27. Hein DW, Grant DM, Sim E: Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10, 291-292 (2000).
28. Wilke RA, Lin DW, Roden DM et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916 (2007). ■■ Summarized genetic variant associated adverse drug reactions and suggested direction for future studies.
29. Lee JE, Choi JH, Lee JH, Lee MG: Gene SNPs and mutations in clinical genetic testing: haplotype-based testing and analysis. Mutat. Res. 573, 195-204 (2005).
30. Zhao H, Pfeiffer R, Gail MH: Haplotype analysis in population genetics and association studies. Pharmacogenomics 4, 171-178 (2003). (Pubitemid 36336456)
31. Lee SY, Lee KA, Ki CS et al.: Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin. Chem. 48, 775-777 (2002).
32. Hein DW, Doll MA, Rustan TD, Ferguson RJ: Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55, 3531-3536 (1995).
33. Walgren JL, Mitchell MD, Thompson DC: Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361 (2005).
34. Sarich TC, Adams SP, Petricca G, Wright JM: Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J. Pharmacol. Exp. Ther. 289, 695-702 (1999). (Pubitemid 29191221)
35. Tafazoli S, Mashregi M, O'Brien PJ: Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol. Appl. Pharmacol. 229, 94-101 (2008). ■ Reported that hydrazine played an important role in isoniazid-induced hepatotoxicity suggesting possible role of amidase.
36. NCBI dbSNP www.ncbi.nlm.gov/SNP/
37. Broad Institute. Medical and Population Genetics: Haploview www.broad.mit.edu/mpg/haploview/index.php
38. Online supplementary Figure 1 www.futuremedicine.com/doi/suppl/10.2217/ pgs.09.100/suppl-file/suppl-fig-1.pdf
39. Online supplementary Figure 2 www.futuremedicine.com/doi/suppl/10.2217/ pgs.09.100/suppl-file/suppl-fig-2.pdf
40. Online supplementary Figure 3 www.futuremedicine.com/doi/suppl/10.2217/ pgs.09.100/suppl-file/suppl-fig-3.pdf
41. Online supplementary Figure 4 www.futuremedicine.com/doi/suppl/10.2217/ pgs.09.100/suppl-file/suppl-fig-4.pdf